Onyvax Limited Publishes Results Of Phase II Prostate Cancer Vaccine Showing Significant Steps Towards Delaying Disease Progression
10/19/2005 5:09:13 PM
London, UK, 17 June 2005: Onyvax Limited, the biotechnology company developing novel cancer therapies, today announced that a paper published recently in Clinical Cancer Research [Vol. 11, 4469-4478], confirms results of the first cohort in a Phase II trial of Onyvax-P, the company’s investigational immunotherapy, showing that it may delay progression in hormone resistant prostate cancer (HRPC) patients. If the effects are repeated in forthcoming randomized trials, the safety and efficacy of this immunotherapy would make it a compelling treatment option for men at this stage of the disease.
comments powered by